Top-Rated Analysts

RBC Capital Updates Long Thesis On LinkedIn; Reiterates Outperform

RBC Capital analyst Mark Mahaney reiterated an Outperform rating on LinkedIn Corp (NYSE:LNKD) with a price target of $245, which implies an upside …

Cantor Remains Optimistic On Oracle Following Fiscal 2Q Results

In a research report published today, Cantor analyst Brian White maintained a Buy rating on Oracle (NYSE:ORCL) with a $48 price target, as the company …

Priceline Currently Offers An Extremely Attractive Entry Point, Says RBC Capital

In a research report sent to investors today, RBC Capital analyst Mark Mahaney reiterated an Outperform rating on Priceline.com (NASDAQ:PCLN) with a $1400 …

Imperial Capital Maintains Outperform On Delta Air Lines Following Investor Day

In a research report sent to investors today, Imperial Capital analyst Bob McAdoo maintained an Outperform rating on Delta Air Lines (NYSE:DAL) with a …

Needham Reiterates Buy On Alnylam Pharmaceuticals Following R&D Day

In a research report released today, Needham analyst Alan Carr reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a price target of …

BMO Comments On Accenture Ahead Of Its Quarterly Conference Call

In a research report issued today, BMO analyst Keith Bachman maintained a Market Perform rating on Accenture Plc (NYSE:ACN) with an $85 price target, ahead of …

Cowen Maintains Outperform On Celgene Following ASH Meeting; Keeps $110 PT

Cowen analyst Eric Schmidt maintained an Outperform rating on Celgene Corporation (NASDAQ:CELG) with a price target of $110, which, surprisingly, represents a potential …

Wedbush Maintains Outperform On Intercept Pharmaceuticals Following PBC Supergroup Meta-Analysis Publication

In a research report issued December 7, 2014, Wedbush analyst Liana Moussatos maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT), as the company announced …

Cowen Maintains Outperform On Sunesis Pharmaceuticals Following Investor Meeting At ASH

In a research report sent to investors, Cowen analyst Eric Schmidt maintained an Outperform rating on Sunesis Pharmaceuticals (NASDAQ:SNSS). No price target was provided.

Cowen Maintains Outperform On Agios Pharmaceuticals As AG-221 Moving In On Pivotal Trials

Cowen analyst Eric Schmidt maintained an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO), as the company announced new data from its ongoing phase 1 trial …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts